Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression
ACR Open Rheumatology · 2025-09 · 7 (9)
DOI: 10.1002/acr2.70085 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 22.09.2025. Verfasst von Jamie E Collins und 14 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital, Boston, Massachusetts. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck KGaA, Novartis, ARTHFN.
Abstract (Originalsprache)
Objective
The Foundation for the National Institutes of Health (FNIH) OA Biomarkers Consortium aims to identify, develop, and qualify biomarkers to support drug development in knee osteoarthritis (OA). The project's second phase, the PROGRESS OA study, aims to externally validate prognostic and response biomarkers identified in the earlier phase (phase 1). Here we present results assessing external validation of prognostic imaging biomarkers.
Design
PROGRESS OA included data from the control arms of several completed randomized controlled trials (RCTs) for symptomatic knee OA. Radiographic progression was defined as joint space width loss (JSWL) ≥0.7 mm. Symptomatic progression was defined as increase of nine or more points in Western Ontario and McMaster Universities Arthritis Index pain (0–100 scale). Imaging biomarkers included quantitative measures of cartilage thickness and semiquantitative (SQ) assessments. Associations between baseline biomarkers and outcomes over 12 to 36 months were examined using logistic regression.
Results
A total of 320 participants from four RCTs were included. Forty‐one participants (13%) had JSWL ≥0.7 mm and 64 (20%) had worsening symptoms. In univariable logistic regression, measures of quantitative and SQ cartilage, SQ Hoffa‐synovitis, effusion‐synovitis, and meniscal extrusion were consistently selected to predict JSWL ≥0.7 mm, similar to phase 1. SQ Hoffa‐synovitis and lateral meniscal damage were consistently selected to predict symptomatic progression. Cross‐validated areas under the curve were 0.69 (95% confidence interval [CI]: 0.53–0.85) for JSWL ≥0.7 mm and 0.77 (95% CI: 0.65–0.87) for symptomatic progression.
Conclusion
The selected prognostic imaging biomarkers are candidates for enriching OA trials for structural and/or symptomatic progressors. Ongoing work includes pursuit of formal biomarker qualification by regulatory agencies, and the use of these biomarkers to capture structural progression with high sensitivity to change.
Autor:innen und Institutionen
- Brigham and Women's Hospital, Boston, Massachusetts.
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersy.
- Machine Learning Section, Department of Computer Science, University of Copenhagen, Copenhagen, Denmark.
- Sydney Musculoskeletal Health, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.
- Center for Anatomy and Cell Biology and Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Paracelsus Medical University, Salzburg, Austria, and Chondrometrics GmbH, Freilassing, Germany.
- Boston University School of Medicine, Boston, and Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts.
ORCID-Profile: Jamie E Collins, Leticia A Deveza, Thomas A Perry, Frank W Roemer, David J Hunter
Förderung
- Merck KGaA
- Novartis
- ARTHFN
- Biosplice Therapeutics Inc
- Pfizer
- Arthritis Foundation
Zitieren
APA
Collins, J. E., Mesenbrink, P., Jin, R., Dam, E. B., Deveza, L. A., Eckstein, F., Guermazi, A., Ladel, C., Perry, T. A., Robinson, D., Roemer, F. W., Swearingen, C. J., Wirth, W., Kraus, V. B., & Hunter, D. J. (2025). Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression. ACR Open Rheumatology, 7(9). https://doi.org/10.1002/acr2.70085
Vancouver
Collins JE, Mesenbrink P, Jin R, Dam EB, Deveza LA, Eckstein F, et al. Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression. ACR Open Rheumatology. 2025;7(9). doi:10.1002/acr2.70085
BibTeX
@article{Collins2025,
author = {Collins, Jamie E and Mesenbrink, Peter and Jin, Rui and Dam, Erik B and Deveza, Leticia A and Eckstein, Felix and Guermazi, Ali and Ladel, Christoph and Perry, Thomas A and Robinson, Douglas and Roemer, Frank W and Swearingen, Christopher J and Wirth, Wolfgang and Kraus, Virginia B and Hunter, David J},
title = {Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression},
journal = {ACR Open Rheumatology},
year = {2025},
volume = {7},
number = {9},
doi = {10.1002/acr2.70085}
}
EUVIMED